American Journal of Cardiology
Volume 105, Issue 5 , Pages 664-666, 1 March 2010

Lipid-Lowering Efficacy of Red Yeast Rice in a Population Intolerant to Statins

  • Carmelo V. Venero, MD

      Affiliations

    • University of Tennessee Medical Center, Knoxville, Tennessee
    • ,
  • Jose V. Venero, MD

      Affiliations

    • Allegheny General Hospital, Pittsburgh, Pennsylvania
    • ,
  • Dale C. Wortham, MD

      Affiliations

    • University of Tennessee Medical Center, Knoxville, Tennessee
    • ,
  • Paul D. Thompson, MD

      Affiliations

    • Henry Low Heart Center, Hartford Hospital, Hartford, Connecticut
    • University of Connecticut, Farmington, Connecticut
    • Corresponding Author InformationCorresponding author: Tel: (860) 545-2880; fax: (860) 545-2882

Received 4 August 2009; received in revised form 13 October 2009; accepted 13 October 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Dr. Wortham is on the Speaker's Bureau of Novartis (East Hanover, New Jersey), Sanofi Aventis (Bridgewater, New Jersey); Dr. Thompson has received grant/research support from Merck (West Point, Pennsylvania), Pfizer (New York, New York), Astra Zeneca (Wilmington, Delaware), B. Braun (Bethlehem, Pennsylvania), GlaxoSmithKline (Research Triangle Pk, North Carolina), Roche (Nutley, New Jersey), and Genomas (Hartford, Connecticut); has been a Consultant to Astra Zeneca, Merck, Schering-Plough (Liberty Corner, New Jersey), Takeda (Deerfield, Illinois), Roche, Genomas, and Abbott (North Chicago, Illinois); has been on the Speaker's Bureau for Merck, Pfizer, Abbott, Astra Zeneca, Schering-Plough, Stock; and has been a shareholder in Zoll (Chelmsford, Massachusetts), General Electric (Fairfield, Connecticut), JA Wiley Publishing (StreetHoboken, New Jersey), Zimmer (West Center Street Warsaw, Indiana), Medtronic (Minneapolis, Minnesota), and Merck. Work performed at the Cholesterol Management Center, Henry Low Heart Center, Hartford Hospital, Hartford, Connecticut.

PII: S0002-9149(09)02588-0

doi:10.1016/j.amjcard.2009.10.045

American Journal of Cardiology
Volume 105, Issue 5 , Pages 664-666, 1 March 2010

Article Tools

* Image Usage & Resolution